← All trials
NCT01057537
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2010
- Primary completion
- Jul 1, 2012
- Completion date
- Sep 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 2004
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- Royal College of Surgeons, IrelandCollaborator
- Public Health Foundation of IndiaCollaborator
- Dr. Reddy's LaboratoriesCollaborator
- Utrecht UniversityCollaborator
- Public Health Foundation of IndiaOverall official - principal investigator
- Dr. Reddy's LaboratoriesOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Utrecht UniversityOverall official - principal investigator
- Royal College of Surgeons, IrelandOverall official - principal investigator
- University of LondonStudy director
- European CommissionCollaborator
- Government of IndiaOverall official - principal investigator
- University of LondonCollaborator
- University of New South WalesCollaborator
- University of New South WalesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.